No—LGE at 12% Cannot Be Attributed to LVH Alone and Demands Urgent Investigation for Underlying Cardiomyopathy
An increase in late gadolinium enhancement from 4% to 12% in an endurance cyclist with LVH is pathological and cannot be explained by physiological hypertrophy alone. This degree and progression of LGE signals myocardial replacement fibrosis requiring immediate evaluation for underlying cardiomyopathy, particularly given the context of long-term testosterone therapy.
Why LGE is NOT Present in Isolated Physiological LVH
The European Association of Preventive Cardiology/European Association of Cardiovascular Imaging guidelines explicitly state that LGE is used to distinguish adaptive athletic changes from disease 1. While the guidelines acknowledge that "small spots of fibrosis have been occasionally reported in endurance athletes without other obvious disease," they emphasize that:
- LGE helps distinguish potentially adaptive changes from diseases in the context of diffuse LV hypertrophy 1
- The presence of LGE is a key differentiating feature between athlete's heart and pathological conditions like HCM 1
- In the diagnostic algorithm for athlete's heart versus HCM, positive LGE on CMR points toward HCM, not physiological adaptation 1
The Significance of 12% LGE
The 2024 AHA/ACC HCM guidelines establish that extensive LGE ≥15% of LV mass represents a significant (2-fold) increase in sudden cardiac death risk 2. Your patient at 12% is approaching this critical threshold, and the tripling of LGE from 4% to 12% represents concerning disease progression.
Recent research confirms that:
- In competitive amateur cyclists, LGE occurred in only 33% of males, and when present was predominantly at the RV insertion point (79%) 3
- Non-RVIP LGE in cyclists was associated with adverse remodeling, reduced RV ejection fraction, and elevated troponin—suggesting a distinct pathological phenotype 3
- The location and extent of LGE matter critically for prognosis
Critical Differential Diagnoses to Exclude
1. Hypertrophic Cardiomyopathy (Most Likely)
The 2020 AHA/ACC HCM guideline notes that CMR with LGE has excellent ability to outline myocardial replacement fibrosis and is commonly used for differentiation between diseased and adaptive athletes 4. In HCM:
- LGE is typically patchy or confluent
- Can occur in various patterns (mid-wall, subepicardial)
- Extensive LGE is associated with increased risk for life-threatening ventricular arrhythmias 2
2. Infiltrative/Storage Diseases
Given the testosterone therapy context, consider:
- Fabry disease: Shows specific mid-wall inferolateral LGE patterns 5, 6
- Amyloidosis: Diffuse subendocardial LGE 1
- Anderson-Fabry disease: Subepicardial basal LGE 1
3. Inflammatory Cardiomyopathy
Mid-wall and subepicardial LGE patterns suggest inflammatory disease-related necrosis or scars (myocarditis, sarcoidosis) 1
4. Arrhythmogenic Cardiomyopathy
Particularly left-dominant variant, which shows fibro-fatty replacement in sub-epicardial or mid-wall regions 7
Testosterone Therapy as a Confounding Factor
The FDA label for testosterone indicates it is approved only for replacement therapy in conditions of testosterone deficiency 8. Long-term use in a male endurance athlete raises concerns about:
- Supraphysiologic dosing potentially contributing to pathological cardiac remodeling
- Increased risk of cardiovascular events
- Possible contribution to myocardial fibrosis development
The testosterone label warns about cardiac risks but does not specifically address LGE development 8.
Immediate Clinical Actions Required
Comprehensive Cardiac Evaluation:
Detailed family history for sudden cardiac death, HCM, or inherited cardiomyopathies
12-lead ECG looking for major abnormalities (ST-segment/T-wave inversions, pathological Q waves)
Echocardiography with strain imaging to assess:
24-hour Holter monitoring and exercise testing to detect ventricular arrhythmias
Genetic testing for sarcomeric mutations (HCM), desmosomal genes (AC), and storage diseases
Cardiopulmonary exercise testing to assess functional capacity
Review testosterone dosing and consider cessation to assess for reversibility
Pattern Analysis of LGE:
The location and distribution of the 12% LGE is critical:
- RV insertion point only: May represent physiological stress (though 12% is still excessive) 3
- Mid-wall inferolateral: Suggests Fabry disease 5, 6
- Patchy/confluent: Suggests HCM 1, 4
- Subendocardial: Consider infiltrative disease 1
Risk Stratification:
The progression from 4% to 12% LGE indicates active disease progression requiring:
- Assessment for ICD candidacy if HCM confirmed 2
- Evaluation for heart failure risk
- Consideration of sports restriction pending diagnosis 7, 1
Common Pitfalls to Avoid
- Attributing significant LGE to "athlete's heart": This is a dangerous assumption that delays diagnosis of treatable cardiomyopathies
- Ignoring the progression: The tripling of LGE extent is never physiological
- Failing to assess LGE pattern: Location matters for differential diagnosis
- Overlooking testosterone as a contributor: Supraphysiologic androgen use may contribute to pathological remodeling
- Delaying genetic testing: Many causes of LGE with LVH are inherited and have treatment implications
Bottom line: 12% LGE with documented progression cannot be dismissed as physiological LVH and requires comprehensive evaluation for underlying cardiomyopathy with potential implications for sudden cardiac death risk, treatment, and sports participation.